BiotechTube

eftilagimod alpha + Paclitaxel

Phase 2/3Active
0 watching 0 views this week⚡ Active
57
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Breast Carcinoma

Conditions

Breast Carcinoma

Trial Timeline

May 22, 2023 → Jul 31, 2027

NCT ID
NCT05747794

About eftilagimod alpha + Paclitaxel

eftilagimod alpha + Paclitaxel is a phase 2/3 stage product being developed by Immutep for Breast Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05747794. Target conditions include Breast Carcinoma.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (2)

NCT IDPhaseStatus
NCT04252768Phase 1Withdrawn
NCT05747794Phase 2/3Active

Competing Products

20 competing products in Breast Carcinoma

See all competitors
ProductCompanyStageHype Score
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
23
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
52
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
52
Abemaciclib + FulvestrantEli LillyPhase 2
52
VS-6766 + Abemaciclib + FulvestrantEli LillyPhase 1/2
41
gemcitabine + vinorelbineEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
33
AbemaciclibEli LillyPre-clinical
23
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
52
arzoxifeneEli LillyApproved
85
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
BBI-940 + FulvestrantBoundless BioPhase 1
25
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
77
pemetrexed + gemcitabineEli LillyPhase 2
52
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: SorafenibEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52

Other Products from Immutep

Eftilagimod Alfa (Efti) + Docetaxel-cyclophosphamide (TC) intravenous (i.v) + Dose dense Adriamycin-cyclophosphamide (AC) i.vPhase 2
44
Pembrolizumab, Eftilagimod alfaPhase 2
44
IMP321 (eftilagimod alpha) + Placebo + PaclitaxelPhase 2
44
2 vaccine injections in 1 limb + 2 vaccine injections in distinct limbs + 2 "vaccine injections" in distinct limbsPhase 1/2
33
Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 + IMP321Phase 1/2
33